United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc.

134 S. Ct. 1759, 188 L. Ed. 2d 592, 572 U.S. 1033, 82 U.S.L.W. 3566, 2014 WL 1271321, 2014 U.S. LEXIS 2309
CourtSupreme Court of the United States
DecidedMarch 31, 2014
DocketNo. 12–1349.
StatusPublished
Cited by5 cases

This text of 134 S. Ct. 1759 (United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc., 134 S. Ct. 1759, 188 L. Ed. 2d 592, 572 U.S. 1033, 82 U.S.L.W. 3566, 2014 WL 1271321, 2014 U.S. LEXIS 2309 (U.S. 2014).

Opinion

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
134 S. Ct. 1759, 188 L. Ed. 2d 592, 572 U.S. 1033, 82 U.S.L.W. 3566, 2014 WL 1271321, 2014 U.S. LEXIS 2309, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-nathan-v-takeda-pharm-n-am-inc-scotus-2014.